Management of Type 2 Diabetes: An Update and Review of Non-Injectable Pharmacological Treatment

1. Nearly 4 in 10 adults who died from COVID-19 in the United States also had diabetes.

a) True
b) False

2. Incident and prevalent end stage renal disease (ESRD) cases was slower in AI/AN than other populations from 2000-2019.

a) True
b) False

3. Beta-cell secretory dysfunction is related to genetics, inflammation or metabolic stress.

a) True
b) False

4. The following is/are critical times to refer to Diabetes Self-Management Education and Support (DSMES):

a) at diagnosis
b) annually
c) when complications develop
d) transitions in life
e) All of the above

5. A vitamin B 12 deficiency can be associated with the use of Metformin in patients.

a) True
b) False

6. The following is/are injectable medications:

a) Delaglutide
b) Exenatide
c) Semaglutide
d) All of the above

7. When heart failure or chronic kidney disease is newly identified, an SGLT-2 inhibitor would be the preferred oral medication to consider.

a) True
b) False

8. The following is/are examples of DPP-4 inhibitors:

a) sitagliptin
b) saxagliptin
c) linagliptin
d) All of the above

9. Sulfonylureas can accelerate beta-cell failure.

a) True
b) False